Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Shareholder Meeting (November 2017)
26 slides from Immutep's shareholder meeting presentation, Nov 20, 2017
Slide 1: Prima BioMed Annual General Meeting CEO Presentation
Prima BioMed Annual General Meeting CEO Presentation November 17, 2017 ASX:PRR; NASDAQ:PBMD Marc Voigt 1
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cl
Slide 3: 2017 Highlights
2017 Highlights Corporate R&D Collaborations Sound financial TACTI-mel two cohorts Ongoing clinical management recruited, 3rd underway development of our First raise in the US – encouraging data partners GSK and (Registered Direct) AIPAC safety run in Novartis Overseas advance tax completed, randomi
Slide 4: Key Financials
Key Financials Ticker ASX PRR;NASDAQ PBMD Market Cap A$63.8M (10 Nov 17) Shares on Issue 2,362,662,532 (10 Nov 17) Net Loss FY17 A$9.4M (FY16: A$62.0M ) G&A Expenses FY17 A$4.3M (FY16: A$7.0M) R&D and IP Expenses FY17 A$7.5M (FY16: A$7.1M) Revenue and other income FY17 A$4.2M (FY16: A$2.0M) Cash in
Slide 5: Program Update & Prima BioMed
PROGRAM UPDATE & PRIMA BIOMED
Slide 6: Oncology and Autoimmune Pipeline
Oncology and Autoimmune Pipeline Eftilagimod Alpha (LAG-3Ig or IMP321), APC Activator – Fusion Protein Partners Preclinical Phase I Phase IIa Phase IIb WW Prima Metastatic Breast (ex China: Eddingpharm) ’17* 2019* Phase IIb trial began Oct 2015 Cancer MOA: APC activator following first-line chemothe
Slide 7: Eftilagimod Alpha (IMP321) Potential Application
Eftilagimod Alpha (IMP321) Potential Application New International Nonproprietary Name granted by international authority (WHO) for IMP321: Eftilagimod Alpha Potential combination therapy strategies: Chemo-immunotherapy in various cancer indications Combination therapy with active agents such as Tax
Slide 8: AIPAC - Active Immunotherapy with PAClitaxel
AIPAC- Active Immunotherapy with PAClitaxel Chemoimmunotherapy – adding an antigen presenting cell (APC) activator after chemotherapy treatment to boost immune responses. Encouraging scientific advice from EMA July 2015 Initiated Dec 2015 First patient dosed Feb 2016 First safety, PK and immune moni
Slide 9: Eftilagimod Alpha – Preliminary Efficacy Metastatic Breast Cancer
Eftilagimod Alpha – Preliminary Efficacy Metastatic Breast Cancer – 1st chemotherapy + IMP321 Our response rates are substantially better than the 22-33 % response rates seen in historical control groups with paclitaxel as a monotherapy P005 – phase I (n=30) AIPAC (P011) – phase I trial (n=15) Respo
Slide 10: TACTI-mel Two ACTive Immunotherapies in melanoma
TACTI-mel Two ACTive Immunotherapies in melanoma Combination therapy – combining an APC activator and a checkpoint inhibitor to kick start the immune response after removing the brake. Initiated Jan 2016 Being conducted at 6 sites in Australia First cohort finished (safety) Dec 2016 Second cohort fi
Slide 11: Eftilagimod Alpha – Preliminary Efficacy Metastatic melanoma
* - according to study protocol patients receive pembrolizumab monotherapy for 3 cycles. Patients suboptimally responding to or progressing on pembrolizumab are screened and receive combination treatment beginning with cycle 5 (after 3 months) onwards Eftilagimod Alpha – Preliminary Efficacy Metasta
Slide 12: pre-pembro week (pembro) week (combo) week (combo) R L R L R L R
pre-pembro week 9 (pembro) week 25 (combo) week 37 (combo) R L R L R L R irPD week 64 (PFS-FU) R L R L
Slide 13: TACTI-mel Patient A4 (1 mg): Preliminary results
TACTI-mel Patient A4 (1 mg): Preliminary results Efficacy: metastatic melanoma - spread to the lung Pre-Pembro week 13 (pembro) week 29 (combo) R L R L R L week 72 (pembro) Tumour burden (irRC) week 40 (combo) 5000 Pembrolizumab tumour burden R L R L 4720 according to irRC 4000 2 ] 3000 burden[mm Pe
Slide 14: TACTI-mel Patient B2 (6 mg): Preliminary results
TACTI-mel Patient B2 (6 mg): Preliminary results Efficacy: metastatic melanoma L R Week 18 (pembro) week 41(combo) R L R L Tumour burden (irRC) 120 Pembrolizumab 100 Pembrolizumab + IMP321 100 2 ] mm 80 en[ subcuteneous urd 60 upper part b r Tumo 40 20 25 25 0 after pembro mono Cycle 5 Cycle 9 18 30
Slide 15: INSIGHT: IMP321 in i.t. and i.p. Application
INSIGHT: IMP321 in i.t. and i.p. Application Investigator Initiated Trial Prof. Al-Batran, IKF, Frankfurt, Germany Population: 18 pts (9 per stratum) with advanced solid tumors w/o standard treatment options Objectives: Recommended phase II dose, PD effects of IMP321 Design: intrapatient escalation
Slide 16: Partnership Updates I
Partnership Updates I GSK2831781, GSK’s investigational product derived from GSK IMP731 antibody, in ongoing clinical trial in the context of autoimmune diseases Phase I study expected to be finished in Aug 2018 Portfolio review at GSK in 2017 -> IMP731 continued despite cancellation of 13 clinical
Slide 17: Partnership Updates II: IMP321
Partnership Updates II: IMP321 Chinese IND for IMP321 submitted in Feb 2017 EOC, an Eddingpharm Spin-out holding the Chinese rights for IMP321, successfully closed $32 Million round for oncology assets in Nov 2017 Milestone and royalty bearing partnership for Prima Spin off from NEC, Japan. Est. Dec
Slide 18: The Market Environment in IO
The Market Environment in IO 18
Slide 19: IO Therapy Landscape and Opportunity
IO Therapy Landscape and Opportunity Current Immuno-Oncology Therapies Evolution of Immuno-Oncology Therapies CTLA-4, PD-1 and PD-L1 antagonists Opdivo/ approved for many indications anti-LAG-3 Opdivo/Yervoy Combo* only 15 - 40% of solid tumors combo respond Yervoy Keytruda/chemo Combo Opdivo + Yerv
Slide 20: IO Sales by Approach (2019-2024)
IO Sales by Approach (2019-2024) IO Sales Are Estimated to Reach $34 billion in 2024 with Checkpoint Inhibitors Accounting for the Largest Market Share Checkpoint Inhibitors Source: Global Data, Immuno-Oncology Strategic Insight: Multi-Indication and 20 Market Size Analysis (May 2016)
Slide 21: Breast Cancer Market Opportunity
Breast Cancer Market Opportunity IO Sales Are Estimated to Reach $34 billion in 2024 with Checkpoint Inhibitors Accounting for the Largest Market Share HER2-Negative Breast Cancer (8 Major Pharma Markets) Key Statistics 2015 Epidemiology HER2- Breast Cancer 910,016 Incident Cases 2015 Market Sales U
Slide 22: IP Portfolio
IP Portfolio Progress made with prosecution of Prima’s global patent portfolio, including a number of new patent grants in key global markets, including: - US 9,579,382 (use of IMP321 in the treatment of cancer) - JP 6,169,734 (use of IMP321 in the treatment of infectious disease) - JP 6,177,735 (IM
Slide 23: Upcoming Milestones & Prima BioMed
UPCOMING MILESTONES & PRIMA BIOMED
Slide 24: Upcoming Milestones
Upcoming Milestones Clinical Other Dec 2017: Update on clinical development Dec 2017: Last patient of 30 mg TACTI-mel expected –expansion planned Throughout 2018: TACTI-mel results from different cohorts Mid 2018: AIPAC should be fully recruited Throughout 2018: Single cases from INSIGHT study Precl
Slide 25: New Logo
New Logo* Potential ticker symbols: ASX: IMM; NASDAQ: IMMP 25 * Name change subject to shareholder approval
Slide 26: Thank you!
NASDAQ: PBMD, ASX: PRR Thank you! 26